Strokes are a major contributor to morbidity and mortality worldwide. Understanding and improving patient outcomes after stroke requires increased knowledge of the underlying processes associated with neurological recovery after stroke.
There is increasing interest in understanding and identifying neurotoxic cytokine products, brain-immune interactions, tissue damage and recovery, and immune cell homeostasis. Immune cell phenotyping and cytokine profiling is a key step towards identifying therapeutic targets to elucidate and alleviate stroke pathogenesis.
Advanced flow cytometry, which combines high-throughput sampling and advanced data analytics, enables rapid cell phenotyping and cytokine quantitation to uncover key insights of inflammatory-related neurobiology.
Key Learning Objectives
The webinar will include:
- An overview of key neuro-immunology types
- Conversation on the significance and use, of immune cell phenotyping and cytokine profiling
- A discussion on the research challenges of brain-immune interactions
- Live Questions and Answers
Prof. Dr. Arthur Liesz, Professor of Experimental Neurology, Ludwig-Maximilians University Munich
Arthur Liesz is a clinician-scientist who has received his training in neurology at the University of Heidelberg Medical Center, in addition he was trained in experimental immunology at the German Cancer Research Institute (DKFZ). His research interest is on immunological aspects of acute brain injury, working on the topic of brain-immune interaction after acute brain injuries for more than a decade. The research encompasses both sides of brain-immune interaction after stroke: the secondary neuroinflammatory reaction to brain damage and the impact of brain injury on the peripheral immune homeostasis. His work provided the first description on the key role of regulatory T cells in limiting an overshooting immune reaction after acute brain injury (Liesz et al., Nature Medicine, 2009).
His laboratory performed preclinical studies (e.g. Liesz et al., Brain, 2011) which have in the meanwhile led to a recently completed clinical Phase II study (ACTION trial). More recently, Dr. Liesz’ lab focuses on the contribution of the gut microbiota to prime the post-ischemic neuroinflammatory response and has described for the first time a bi-directional link between the brain and gut microbiota in acute brain ischemia (e.g. Singh et al., J Neuroscience, 2016). Dr. Liesz is currently heading the "Laboratory of Stroke-Immunology" at the Institute for Stroke and Dementia Research in Munich, Germany.